HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Harada, M. Articles by Itoh, K. Search for Related Content PubMed PubMed Citation Articles by Harada, M. Articles by Itoh, K.

In Vivo Evidence That Peptide Vaccination Can Induce HLA-DR-Restricted CD4⁺ T Cells Reactive to a Class I Tumor Peptide ¹

Mamoru Harada^2,*, Rumi Gohara, Satoko Matsueda^*, Akira Muto^*, Tatsuya Oda, Yoshiko Iwamoto and Kyogo Itoh^*

Departments of ^* Immunology and Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan; and Division of Biochemistry, Faculty of Fisheries, Nagasaki University, Nagasaki, Japan

Vaccination with class I tumor peptides has been performed to induce tumor-reactive CD8⁺ T cells in vivo. However, the kinds of immune responses that vaccination might elicit in patients are not fully understood. In this study we tried to elucidate the mechanisms by which vaccination of class I binding tumor peptides into an HLA-A2⁺ lung cancer patient elicited dramatic amounts of IgG1 and IgG2 specific to a nonamer peptide, ubiquitin-conjugated enzyme variant Kua (UBE2V)_43–51. The UBE2V_43–51 peptide contains cysteine at the sixth position. HLA-DR-restricted and UBE2V_43–51 peptide-recognizing CD4⁺ T cells were induced from postvaccination, but not from prevaccination, PBMCs of the cancer patient. In addition, a CD4⁺ T cell line (UB-2) and its clone (UB-2.3), both of which recognize the UBE2V_43–51 peptide in the context of HLA-DRB1*0403 molecules, were successfully established from postvaccination PBMCs. The peptide vaccination increased the frequency of peptide-specific T cells, especially CD4⁺ T cells. In contrast, mass spectrometric analysis revealed that the vaccinated UBE2V_43–51 peptide contained both monomeric and dimeric forms. Both forms, fractionated by reverse phase HPLC, were recognized by UB-2 and UB-2.3 cells. Recognition by these CD4⁺ T cells was observed despite the addition of a reduction reagent or the fixation of APC. Overall, these results indicate that vaccination with class I tumor peptides can induce HLA-DR-restricted CD4⁺ T cells in vivo and elicit humoral immune responses, and that a cysteine-containing peptide can be recognized by CD4⁺ T cells not only as a monomer, but also as a dimer.